米拉贝隆治疗膀胱过度活动症的安全性和有效性:大型整合临床试验数据库分析
该研究汇总了10项2-4期双盲12周米拉贝隆单药治疗成人膀胱过度活动症(OAB)的研究数据,评估不同年龄和性别亚组的安全性与疗效。结果显示未发现新的安全性问题,米拉贝隆、索利那新和托特罗定均能改善OAB症状,但部分疗效指标存在治疗与亚组的显著交互作用。
要点
- 米拉贝隆25/50mg、索利那新和托特罗定在成人OAB中总体安全有效,未发现新的安全性信号。
- 与安慰剂相比,所有治疗组均改善了尿失禁发作、排尿次数、尿急发作、每次排尿量和夜尿次数。
- 年龄和既往OAB用药史可影响部分疗效指标的变化,需关注个体化治疗。
核心结论
- 来自10项米拉贝隆研究的整合数据库重申了米拉贝隆、索利那新和托特罗定在不同年龄和性别成人中的安全性和有效性。
研究设计与样本
- 汇总分析10项2-4期双盲12周米拉贝隆单药治疗成人OAB研究的数据,纳入至少接受一剂研究药物的患者。
- 干预包括米拉贝隆25和50mg、索利那新2.5/5/10mg和托特罗定缓释4mg。
- 按年龄(<65 vs ≥65岁和<75 vs ≥75岁)和性别进行亚组分析,安全性采用治疗中出现的不良事件比例评估,疗效变量源自膀胱日记(基线和第12周)。
主要发现
- 基线高血压和糖尿病在老年组比年轻组更常见,男性比女性更常见;同一性别内各治疗组间频率相似。
- 未发现之前未报告的安全性问题。
- 与安慰剂相比,所有治疗组在平均每24小时尿失禁发作次数、排尿次数、尿急发作次数、每次排尿量和夜尿次数方面均有改善。
- 显著的治療与亚组交互作用包括:年龄(<65 vs ≥65岁)对每24小时尿失禁发作次数变化的影响、年龄(<65 vs ≥65岁和<75 vs ≥75岁)对夜尿变化的影响、既往OAB用药对尿急发作变化的影响。
临床怎么用
- 米拉贝隆可作为OAB患者抗毒蕈碱药物的替代选择,尤其需关注老年和男性患者基线高血压和糖尿病更常见的情况。
- 治疗决策时应考虑年龄和既往OAB用药史对疗效的影响,个体化评估症状改善。
局限性
- 索利那新2.5和10mg组因患者数量少未纳入疗效分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mirabegron, a β3-adrenoreceptor agonist, is an alternative drug to antimuscarinics for overactive bladder (OAB) symptoms. OBJECTIVE: To summarise safety and efficacy reporting of mirabegron treatment for OAB symptoms. DESIGN, SETTING, AND PARTICIPANTS: Pooled data analysed from 10 phase 2-4, double-blind, 12-wk mirabegron monotherapy studies in adults with OAB who had received one or more doses of study drug. INTERVENTION: Mirabegron: 25 and 50mg; antimuscarinics: solifenacin (2.5, 5, and 10mg) and tolterodine extended release (4mg). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline OAB-related characteristics, intrinsic and extrinsic factors, and analyses by age (<65 vs ≥65yr and <75 vs ≥75yr) and sex were assessed. Solifenacin 2.5 and 10mg groups were not included in the efficacy analyses (small patient numbers). Safety was evaluated using the proportion of treatment-emergent adverse events. Efficacy variables were derived from bladder diaries (baseline and week 12). RESULTS AND LIMITATIONS: Baseline hypertension and diabetes were more frequent across treatment groups in the older versus younger age groups and in men versus women. Within sexes, frequencies were similar between treatment groups. Some differences were observed in baseline characteristics, including type of incontinence and medical history between sexes. No previously unreported safety concerns were identified. Improvements in efficacy (mean number of incontinence episodes/24h, micturitions/24h, urgency episodes/24h, volume voided/micturition, and nocturia episodes) versus placebo were observed in all treatment groups. Significant treatment-by-subgroup interactions included change from baseline in the mean number of incontinence episodes/24h by age (<65 vs ≥65yr), nocturia by age (<65 vs ≥65yr and <75 vs ≥75yr), and urgency episodes by previous OAB medication. CONCLUSIONS: Data from this integrated database of 10 mirabegron studies reaffirm the safety and efficacy profiles of mirabegron, solifenacin, and tolterodine in adults of different age groups and sexes. PATIENT SUMMARY: Overactive bladder is a complex of symptoms including a compelling desire to pass urine that leads to increased frequency, which may lead to a degree of incontinence if you do not reach the toilet in time and may wake you from sleep. We pooled data from 10 different studies of mirabegron in patients with overactive bladder symptoms, and looked at the effect in the total number of patients who received the treatment, as well as in different age groups and between men and women. No new safety concerns were identified, and mirabegron improved the symptoms of overactive bladder.
引用
- Chapple CR, Cruz F, Cardozo L, et al. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Eur Urol. 2019. PMID: 31635815. doi:10.1016/j.eururo.2019.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。